HuGE Literature Finder
Records
1
-
24
| JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome. Journal of cancer research and clinical oncology 2022 Oct . Kandu?a Zuzanna, Janowski Micha?, Wi?ckowska Barbara, Paczkowska Edyta, Lewandowski Krzyszt |
| Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia. European journal of haematology 2022 Oct . Morishita Soji, Hashimoto Yoshinori, Furuya Chiho, Edahiro Yoko, Ochiai Tomonori, Shirane Shuichi, Inano Tadaaki, Yasuda Hajime, Ando Miki, Araki Marito, Komatsu Nor |
| [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2022 6 43 (4): 323-329. Tan Y X, Luo J, Huang J X, Luo D M, Liang H Y, Zhou X, Liu X L, Xu |
| Lab tests for MPN. International review of cell and molecular biology 2022 2 366 187-220. Moncada Alice, Pancrazzi Alessand |
| Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American journal of hematology 2021 (7): 781-789. Gangat Naseema, Guglielmelli Paola, Szuber Natasha, Begna Kebede H, Patnaik Mrinal M, Litzow Mark R, Al-Kali Aref, Foran James M, Palmer Jeanne M, Alkhateeb Hassan, Elliott Michelle A, Hanson Curtis A, Pardanani Animesh, Mannelli Francesco, Vannucchi Alessandro M, Tefferi Ayal |
| Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era. Journal of clinical medicine 2021 Mar 10 (5): . Lee Jong-Mi, Lee Howon, Eom Ki-Seong, Lee Sung-Eun, Kim Myungshin, Kim Yongg |
| A case of a primary myelofibrosis with progression and related literature review of progression phase genetics. International journal of laboratory hematology 2021 7 43 Suppl 1 78-81. Chen Dong, Fuda Franklin, Weinberg Ol |
| Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression. European journal of haematology 2021 1 106 (4): 520-528. Bartels Stephan, Vogtmann Julia, Schipper Elisa, Büsche Guntram, Schlue Jerome, Lehmann Ulrich, Kreipe Ha |
| Thiol/Disulfide Balance in Older Patients with BCR-ABL Negative Myeloproliferative Neoplasms. Clinical laboratory 2021 12 67 (12): . Koyuncu Mahmut B, Cavusoglu Cagatay, Basir Hakan, Ilgan Mustafa, Ucar Mehmet A, Akdeniz Aydan, Tombak Anil, Tiftik Eyup N, Temel Gulhan O, Neselioglu Salim, Erel Ozc |
| [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020 8 41 (7): 576-582. Tan Y X, Xu N, Huang J X, Wu W E, Liu L, Zhou L L, Liu X L, Yin C X, Xu D, Zhou |
| The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. Anticancer research 2019 Nov 39 (11): 6273-6282. Byun Ja Min, Song Seulki, Koh Youngil, Yoon Sung-Soo, Kim Daeyo |
| Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood 2019 2 133 (20): 2233-2242. Gagelmann Nico, Ditschkowski Markus, Bogdanov Rashit, Bredin Swann, Robin Marie, Cassinat Bruno, Shahswar Rabia, Thol Felicitas, Heuser Michael, Socié Gerard, Beelen Dietrich, Triviai Ioanna, Badbaran Anita, Kröger Nicola |
| Mutational profiling in myelofibrosis: implications for management. International journal of hematology 2019 10 111 (2): 192-199. Bose Prithviraj, Verstovsek Srd |
| Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes, chromosomes & cancer 2019 7 59 (1): 30-39. Courtier Frédéric, Garnier Séverine, Carbuccia Nadine, Guille Arnaud, Adélaide José, Chaffanet Max, Hirsch Pierre, Paz Damien Luque, Slama Bohrane, Vey Norbert, Ugo Valérie, Delhommeau François, Rey Jérome, Birnbaum Daniel, Murati An |
| Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. American journal of clinical pathology 2017 May 147 (5): 444-452. Song Jinming, Hussaini Mohammad, Zhang Hailing, Shao Haipeng, Qin Dahui, Zhang Xiaohui, Ma Zhenjun, Hussnain Naqvi Syeda Mahrukh, Zhang Ling, Moscinski Lynn |
| TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish journal of haematology : official journal of Turkish Society of Haematology 2017 Feb . Soyer Nur, Tezcanl? Kaymaz Burçin, Cömert Özkan Melda, Aktan Ça?da?, Küçükaslan Ali ?ahin, ?ahin Fahri, Kosova Buket, Saydam Gür |
| Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clinic proceedings 2017 8 92 (8): 1283-1290. Tefferi Ayalew, Vannucchi Alessandro Mar |
| Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Annals of hematology 2017 11 97 (3): 443-451. Senín Alicia, Fernández-Rodríguez Concepción, Bellosillo Beatriz, Camacho Laura, Longarón Raquel, Angona Anna, Besses Carles, Álvarez-Larrán Alber |
| Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood cancer journal 2017 12 7 (12): 662. Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson C A, Ketterling R P, Pardanani A, Gangat N, Tefferi |
| Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American journal of hematology 2016 Apr . Rotunno Giada, Pacilli Annalisa, Artusi Valentina, Rumi Elisa, Maffioli Margherita, Delaini Federica, Brogi Giada, Fanelli Tiziana, Pancrazzi Alessandro, Pietra Daniela, Bernardis Isabella, Belotti Clara, Pieri Lisa, Sant'Antonio Emanuela, Salmoiraghi Silvia, Cilloni Daniela, Rambaldi Alessandro, Passamonti Francesco, Barbui Tiziano, Manfredini Rossella, Cazzola Mario, Tagliafico Enrico, Vannucchi Alessandro M, Guglielmelli Pao |
| Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood 2013 Aug 122 (6): 893-901. Quintás-Cardama Alfonso, Abdel-Wahab Omar, Manshouri Taghi, Kilpivaara Outi, Cortes Jorge, Roupie Anne-Laure, Zhang Su-Jiang, Harris David, Estrov Zeev, Kantarjian Hagop, Levine Ross L, Verstovsek Srd |
| Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes, chromosomes & cancer 2012 Aug 51 (8): 743-55. Brecqueville Mandy, Rey Jérôme, Bertucci François, Coppin Emilie, Finetti Pascal, Carbuccia Nadine, Cervera Nathalie, Gelsi-Boyer Véronique, Arnoulet Christine, Gisserot Olivier, Verrot Denis, Slama Borhane, Vey Norbert, Mozziconacci Marie-Joelle, Birnbaum Daniel, Murati An |
| TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Annals of hematology 2012 Apr 91 (4): 533-41. Martínez-Avilés Luz, Besses Carlos, Álvarez-Larrán Alberto, Torres Erica, Serrano Sergi, Bellosillo Beatr |
| Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica 2011 Oct 96 (10): 1462-9. Stein Brady L, Williams Donna M, O'Keefe Christine, Rogers Ophelia, Ingersoll Roxann G, Spivak Jerry L, Verma Amit, Maciejewski Jarek P, McDevitt Michael A, Moliterno Alison |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 31, 2023
- Content source: